Primary hyperparathyroidism induces erythropoietin resistance through fibroblast growth factor 23
Authors' conclusion
Anemia in PHPT is linked to elevated FGF23 levels, potentially causing EPO resistance.
Study context
- Population
- Primary hyperparathyroidism (PHPT) patients scheduled for PTX, followed for 6 months (2018–2020); 81% women, median age 64, normal BMI
- Participants
- 111 patients
- Exposure
- Before vs after parathyroidectomy
- Outcome
- Effect of PHPT on erythropoiesis: Hb, EPO and FGF23 levels before and after PTX
- Follow-up
- Baseline (surgery day), 10 days and 6 months postsurgery
Methodological detailsmonocentric
- Monocentric
Main finding
As reported in the abstract
Anemia prevalence · baseline to 6 months post-PTX
- Anemia prevalence at baseline
- 9.9%
- Anemia prevalence 6 months post-PTX
- 2.7%
- Before surgery, FGF23 vs hemoglobin (Hb) (Pearson R)
- R = −0.20, P = .020
- Before surgery, FGF23 vs log-EPO (Pearson R)
- R = 0.38, P < .001
- Multivariable models: FGF23 and declining Hb (β, 95% CI)
- β = −.01, 95% CI [−0.02; −0.01]
Observational data: associations, not effects.
Original publication
Primary hyperparathyroidism induces erythropoietin resistance through fibroblast growth factor 23. Eur J Endocrinol. Published 11 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →